Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASTERN Study: Real-world efficacy and safety of Dorzagliatin in type 2 diabetes
ChiCTR2600117249Phase 4Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dorzagliatin in type 2 diabetes mellitus (T2DM), sponsored by Shanghai General Hospital. Primary endpoints: Hypoglycemia incidence rate and Proportion of patients with glycated hemoglobin <7%. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
dorzagliatin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2600117249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117249.